Thrombotic thrombocytopenic purpura secondary prevention: Difference between revisions
No edit summary |
|||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Effective measures for the secondary prevention of TTP include: prevention any further clinically significant allergic or anaphylactic | Effective [[Measure theory|measures]] for the [[Secondary Prevention|secondary prevention]] of TTP include: [[prevention]] any further clinically [[Significance|significant]] [[allergic]] or [[anaphylactic]] [[reaction]]<nowiki/>s and facilitated both [[patients]]’ TTP (inherited and acquired thrombotic thrombocytopenic purpura) remissions. | ||
==Secondary Prevention== | ==Secondary Prevention== | ||
Effective measures for the secondary prevention of TTP is prevention any further | Effective measures for the secondary prevention of TTP is [[prevention]] any further [[Clinical|clinica]]<nowiki/>lly significant [[allergic]] or [[anaphylactic]] [[Reactions on surfaces|reactions]] and facilitated both patients’ TTP ([[inherited]] and [[acquired]] thrombotic thrombocytopenic purpura) remissions. [[Patient|Patients]] who had TTP should be obsereved for [[signs]] and [[Symptom|symptoms]] of [[relapse]]. | ||
* | *Factors that may [[trigger]] TTP or [[relapse]], including: | ||
** Pregnancy | ** [[Pregnancy]] | ||
** Diseases such as cancer, HIV, lupus | ** [[Disease|Diseases]] such as [[cancer]], [[HIV]], [[lupus]] and [[Infection|infections]]. | ||
** Medical procedures, such as surgery | ** [[Medical procedure|Medical procedures]], such as [[surgery]], [[blood]] and [[marrow]] [[stem cell]] [[transplant]]. | ||
** Medicines, such as ticlopidine, clopidogrel, cyclosporine A, chemotherapy, and hormone therapy(estrogens). | ** Medicines, such as [[ticlopidine]], [[clopidogrel]], [[cyclosporine]] A, [[chemotherapy]], and [[hormone therapy]]([[Estrogen|estrogens]]). | ||
** Quinine | ** Quinine | ||
Revision as of 16:47, 5 October 2018
|
Xyz Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Thrombotic thrombocytopenic purpura secondary prevention On the Web |
|
American Roentgen Ray Society Images of Thrombotic thrombocytopenic purpura secondary prevention |
|
FDA on Thrombotic thrombocytopenic purpura secondary prevention |
|
CDC on Thrombotic thrombocytopenic purpura secondary prevention |
|
Thrombotic thrombocytopenic purpura secondary prevention in the news |
|
Blogs on Thrombotic thrombocytopenic purpura secondary prevention |
|
Risk calculators and risk factors for Thrombotic thrombocytopenic purpura secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Effective measures for the secondary prevention of TTP include: prevention any further clinically significant allergic or anaphylactic reactions and facilitated both patients’ TTP (inherited and acquired thrombotic thrombocytopenic purpura) remissions.
Secondary Prevention
Effective measures for the secondary prevention of TTP is prevention any further clinically significant allergic or anaphylactic reactions and facilitated both patients’ TTP (inherited and acquired thrombotic thrombocytopenic purpura) remissions. Patients who had TTP should be obsereved for signs and symptoms of relapse.
- Factors that may trigger TTP or relapse, including:
- Pregnancy
- Diseases such as cancer, HIV, lupus and infections.
- Medical procedures, such as surgery, blood and marrow stem cell transplant.
- Medicines, such as ticlopidine, clopidogrel, cyclosporine A, chemotherapy, and hormone therapy(estrogens).
- Quinine